TrialFrontiers in immunology2023

Real-world clinical effectiveness of Tixagevimab/Cilgavimab and Regdanvimab monoclonal antibodies for COVID-19 treatment in Omicron variant-dominant period.

Daria S Fomina et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.